LIFECORE BIOMEDICAL, INC. Revenue from Contract with Customer, Including Assessed Tax
LIFECORE BIOMEDICAL, INC. (LFCR) reported Revenue from Contract with Customer, Including Assessed Tax of $34.17 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2026-08-05
- LIFECORE BIOMEDICAL, INC. revenue from contract with customer, including assessed tax for the quarter ending 2026-06-30 was $34.17M.
- LIFECORE BIOMEDICAL, INC. revenue from contract with customer, including assessed tax for the quarter ending 2026-03-31 was $23.19M.
- LIFECORE BIOMEDICAL, INC. revenue from contract with customer, including assessed tax for the quarter ending 2025-09-30 was $31.11M.
- LIFECORE BIOMEDICAL, INC. revenue from contract with customer, including assessed tax for the quarter ending 2025-05-25 was $36.44M, a 3.81% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. revenue from contract with customer, including assessed tax for fiscal 2025 was $128.87M, a 0.47% increase from fiscal 2024.
- LIFECORE BIOMEDICAL, INC. revenue from contract with customer, including assessed tax for fiscal 2024 was $128.26M, a 24.20% increase from fiscal 2023.
- LIFECORE BIOMEDICAL, INC. revenue from contract with customer, including assessed tax for fiscal 2023 was $103.27M, a 7.19% decline from fiscal 2022.
- LIFECORE BIOMEDICAL, INC. revenue from contract with customer, including assessed tax for fiscal 2022 was $111.27M, a 10.31% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 1 month | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Including Assessed Tax 7 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 9 month as first filed | Revenue from Contract with Customer, Including Assessed Tax 12 month | Revenue from Contract with Customer, Including Assessed Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $34.17M 10-Q · filed 2026-08-05 | $57.36M 10-Q · filed 2026-08-05 | ||||||||
| 2026-03-31 | $23.19M 10-Q · filed 2026-05-06 | |||||||||
| 2025-12-31 | $75.52M 10-KT · filed 2026-03-16 | |||||||||
| 2025-09-30 | $31.11M 10-Q · filed 2025-11-06 | |||||||||
| 2025-06-30 | $8.66M 10-KT · filed 2026-03-16 | |||||||||
| 2025-05-25 | $36.44M 10-Q · filed 2026-08-05 | $71.60M 10-Q · filed 2026-08-05 | $104.16M derived: sum of 3 quarters · filed 2026-08-05 | $128.87M 10-KT · filed 2026-03-16 | ||||||
| 2025-02-23 | $35.15M 10-Q · filed 2026-05-06 | $67.72M derived: sum of 2 quarters · filed 2026-05-06 | $92.42M 10-Q · filed 2025-04-03 | $130.31M derived: sum of 4 quarters · filed 2026-05-06 | ||||||
| 2024-12-31 | $62.96M 10-KT · filed 2026-03-16 | |||||||||
| 2024-11-24 | $32.56M 10-Q · filed 2025-01-02 | $57.27M 10-Q · filed 2025-01-02 | $95.16M derived: sum of 3 quarters · filed 2026-03-16 | $130.86M derived: sum of 4 quarters · filed 2026-03-16 | ||||||
| 2024-08-25 | $24.70M 10-Q · filed 2025-11-06 | $62.59M derived: sum of 2 quarters · filed 2026-03-16 | $98.30M derived: sum of 3 quarters · filed 2026-03-16 | $128.44M derived: sum of 4 quarters · filed 2026-03-16 | ||||||
| 2024-05-26 | $37.89M derived: 10-KT 12 month − 10-Q 9 month · filed 2026-03-16 | $73.59M derived: sum of 2 quarters · filed 2026-03-16 | $103.74M derived: sum of 3 quarters · filed 2026-03-16 | $128.26M 10-KT · filed 2026-03-16 | ||||||
| 2024-02-25 | $35.70M 10-Q · filed 2025-04-03 | $65.85M derived: sum of 2 quarters · filed 2025-04-03 | $90.38M 10-Q · filed 2025-04-03 | $121.52M derived: sum of 4 quarters · filed 2025-04-03 | ||||||
| 2023-11-26 | $30.15M 10-Q · filed 2025-01-02 | $54.67M 10-Q · filed 2025-01-02 | $85.82M derived: sum of 3 quarters · filed 2025-01-02 | $112.35M derived: sum of 4 quarters · filed 2025-01-02 | ||||||
| 2023-08-27 | $24.52M 10-Q · filed 2024-10-04 | $55.67M derived: sum of 2 quarters · filed 2024-10-04 | $82.20M derived: sum of 3 quarters · filed 2024-10-04 | $104.07M derived: sum of 4 quarters · filed 2024-10-04 | ||||||
| 2023-05-28 | $31.14M 10-K · filed 2024-03-20 | $57.68M derived: sum of 2 quarters · filed 2024-08-09 | $79.55M derived: sum of 3 quarters · filed 2024-08-09 | $103.27M 10-K · filed 2024-08-26 | ||||||
| 2023-02-26 | $26.54M 10-Q · filed 2024-08-09 | $27.60M 10-Q · filed 2023-06-02 | $48.40M derived: sum of 2 quarters · filed 2024-08-09 | $72.12M 10-Q · filed 2024-08-09 | $77.75M 10-Q · filed 2023-06-02 | $100.23M derived: sum of 4 quarters · filed 2024-08-09 | ||||
| 2022-11-27 | $21.86M 10-Q · filed 2024-08-09 | $38.80M 10-Q · filed 2023-03-16 | $45.59M 10-Q · filed 2024-08-09 | $82.16M 10-Q · filed 2023-03-16 | $73.69M derived: sum of 3 quarters · filed 2024-08-09 | $108.93M derived: sum of 4 quarters · filed 2024-08-09 | ||||
| 2022-08-28 | $23.72M 10-Q · filed 2024-08-09 | $43.35M 10-Q · filed 2022-10-07 | $51.83M derived: sum of 2 quarters · filed 2024-08-09 | $87.06M derived: sum of 3 quarters · filed 2024-08-09 | $112.66M derived: sum of 4 quarters · filed 2024-08-09 | |||||
| 2022-05-29 | $28.11M 10-K · filed 2024-03-20 | $47.63M 10-K · filed 2022-09-14 | $63.34M derived: sum of 2 quarters · filed 2024-03-20 | $88.94M derived: sum of 3 quarters · filed 2024-03-20 | $111.27M 10-K · filed 2024-08-26 | $185.79M 10-K · filed 2022-09-14 | ||||
| 2022-02-27 | $35.23M 10-K · filed 2024-03-20 | $53.07M 10-Q · filed 2022-04-07 | $60.83M derived: sum of 2 quarters · filed 2024-03-20 | $90.14M 10-Q · filed 2023-06-02 | $138.16M 10-Q · filed 2022-04-07 | $128.08M derived: sum of 4 quarters · filed 2024-03-20 | ||||
| 2021-11-28 | $25.60M 10-K · filed 2024-03-20 | $129.49M 10-Q · filed 2022-01-07 | $85.08M 10-Q · filed 2023-03-16 | $258.28M 10-Q · filed 2022-01-07 | $92.85M derived: sum of 3 quarters · filed 2024-03-20 | $120.65M derived: sum of 4 quarters · filed 2024-03-20 | ||||
| 2021-08-29 | $22.33M 10-K · filed 2024-03-20 | $128.79M 10-Q · filed 2021-10-05 | $67.25M derived: sum of 2 quarters · filed 2024-03-20 | $95.05M derived: sum of 3 quarters · filed 2024-03-20 | $118.84M derived: sum of 4 quarters · filed 2024-03-20 | |||||
| 2021-05-30 | $44.92M 10-K/A · filed 2023-03-16 | $139.83M 10-K · filed 2021-07-29 | $72.72M derived: sum of 2 quarters · filed 2024-03-20 | $96.52M derived: sum of 3 quarters · filed 2024-03-20 | $100.87M 10-K · filed 2024-03-20 | $544.16M 10-K · filed 2021-07-29 | ||||
| 2021-02-28 | $27.81M 10-K · filed 2024-03-20 | $137.78M 10-Q · filed 2021-04-08 | $51.60M derived: sum of 2 quarters · filed 2024-03-20 | $126.63M 10-Q · filed 2022-04-07 | $404.33M 10-Q · filed 2021-04-08 | $230.41M derived: sum of 4 quarters · filed 2024-03-20 | ||||
| 2020-11-29 | $23.79M 10-K · filed 2024-03-20 | $130.90M 10-Q · filed 2021-01-07 | $266.55M 10-Q · filed 2022-01-07 | $202.60M derived: sum of 3 quarters · filed 2024-03-20 | $355.53M derived: sum of 4 quarters · filed 2024-03-20 | |||||
| 2020-08-30 | $22.68M 10-K · filed 2024-03-20 | $135.64M 10-Q · filed 2020-10-07 | $178.81M derived: sum of 2 quarters · filed 2024-03-20 | $331.73M derived: sum of 3 quarters · filed 2024-03-20 | $474.33M derived: sum of 4 quarters · filed 2024-03-20 | |||||
| 2020-05-31 | $156.13M 10-K · filed 2021-07-29 | $309.06M derived: sum of 2 quarters · filed 2021-07-29 | $451.65M derived: sum of 3 quarters · filed 2021-07-29 | $160.07M 10-K/A · filed 2023-03-16 | $590.37M 10-K · filed 2020-08-14 | |||||
| 2020-02-23 | $152.93M 10-K · filed 2021-07-29 | $295.52M derived: sum of 2 quarters · filed 2021-07-29 | $434.24M 10-Q · filed 2021-04-08 | $587.01M derived: sum of 4 quarters · filed 2021-07-29 | ||||||
| 2019-11-24 | $142.59M 10-K · filed 2021-07-29 | $281.31M 10-Q · filed 2021-01-07 | $434.09M derived: sum of 3 quarters · filed 2021-07-29 | $589.64M derived: sum of 4 quarters · filed 2021-07-29 | ||||||
| 2019-08-25 | $138.71M 10-K · filed 2021-07-29 | $291.49M derived: sum of 2 quarters · filed 2021-07-29 | $447.05M derived: sum of 3 quarters · filed 2021-07-29 | $571.61M derived: sum of 4 quarters · filed 2021-07-29 | ||||||
| 2019-05-26 | $152.78M 10-K · filed 2020-08-14 | $308.33M derived: sum of 2 quarters · filed 2020-08-14 | $432.89M derived: sum of 3 quarters · filed 2020-08-14 | $557.56M 10-K · filed 2021-07-29 | ||||||
| 2019-02-24 | $155.55M 10-K · filed 2020-08-14 | $155.69M 10-Q · filed 2019-04-04 | $280.11M derived: sum of 2 quarters · filed 2020-08-14 | $404.78M 10-Q · filed 2020-04-03 | $405.27M 10-Q · filed 2019-04-04 | $545.86M derived: sum of 4 quarters · filed 2020-08-14 | ||||
| 2018-11-25 | $124.56M 10-K · filed 2020-08-14 | $124.91M 10-Q · filed 2019-01-07 | $249.22M 10-Q · filed 2020-01-02 | $249.58M 10-Q · filed 2019-01-07 | $390.30M derived: sum of 3 quarters · filed 2020-08-14 | $535.21M derived: sum of 4 quarters · filed 2020-08-14 | ||||
| 2018-08-26 | $124.67M 10-K · filed 2020-08-14 | $265.74M derived: sum of 2 quarters · filed 2020-08-14 | $410.65M derived: sum of 3 quarters · filed 2020-08-14 | $533.11M derived: sum of 4 quarters · filed 2020-08-14 | ||||||
| 2018-05-27 | $141.08M derived: 10-K 12 month − 10-Q 9 month · filed 2020-08-14 | $285.99M derived: sum of 2 quarters · filed 2020-08-14 | $408.45M derived: sum of 3 quarters · filed 2020-08-14 | $524.23M 10-K · filed 2020-08-14 | ||||||
| 2018-02-25 | $144.91M 10-Q · filed 2019-04-04 | $267.37M derived: sum of 2 quarters · filed 2019-04-04 | $383.15M 10-Q · filed 2019-04-04 | |||||||
| 2017-11-26 | $122.46M 10-Q · filed 2019-01-07 | $238.24M 10-Q · filed 2019-01-07 | ||||||||
| 2017-08-27 | $115.78M 10-Q · filed 2018-10-05 | |||||||||
| 2017-05-28 | $469.78M 10-K · filed 2019-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |